Clinical Implications of the DREAM Study
Response to Kanat
- From the Clinical Center for Research Excellence, Charles R. Drew University, Los Angeles, California
- Address correspondence to Dr. Mayer B. Davidson, Charles R. Drew University, Clinical Center for Rearch Excellence, 1731 E. 120th St., Los Angeles, CA 90059. E-mail: mayerdavidson{at}cdrewu.edu
Because impaired fasting glucose (IFG) in the DREAM study (1) was defined at the time of recruitment as a fasting plasma glucose (FPG) concentration of ≥6.1 to <7.0 mmol/l (110–125 mg/dl), Dr. Kanat (2) raises the possibility that patients with FPG levels of 5.6–6.0 mmol/l (100–109 mg/dl), which …
